Losartan Cost in Delaware 2026: Cash Price, Medicaid, Insurance, and Compounding

What Is Losartan and Why Does Delaware Pricing Matter?

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA for three indications: hypertension, reduction of stroke risk in patients with left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes [1]. It also carries a widely accepted off-label use in heart failure. Because cardiovascular disease remains the leading cause of death in Delaware, with the CDC reporting that heart disease accounts for approximately 22.8% of all Delaware deaths annually, the real-world cost of a daily antihypertensive like losartan directly affects patient adherence and outcomes [2].

Prices in the United States vary dramatically based on whether a patient pays cash, uses insurance, qualifies for Medicaid, or obtains a compounded formulation. Delaware residents face the same fragmented pricing system seen nationwide, though several state-specific factors shift the numbers in ways that matter in 2026.

Generic losartan potassium has been available since 2010, when Merck's patent on Cozaar expired. That patent expiration drove prices down sharply. Today, generic losartan 50 mg (30-tablet supply) lists at roughly $10 per month at most Delaware retail chains, though the exact figure depends on the dispensing pharmacy, the specific dose, and whether a discount card is applied [3].

Current Cash Price for Losartan in Delaware (2026)

The average cash-pay price for generic losartan across Delaware retail pharmacies in 2026 is approximately $10 per month for a standard 50 mg once-daily regimen. That figure does not require any insurance, coupon, or special program.

Several factors influence the exact number a patient sees at the counter. First, dose size matters: losartan 100 mg tablets are not always priced proportionally higher than 50 mg tablets, so splitting 100 mg tablets (only when a prescriber explicitly approves) might cut costs further. Second, pharmacy choice matters. Independent pharmacies in Wilmington and Dover sometimes offer lower prices than national chains due to their membership in buying cooperatives. Third, GoodRx-style discount cards, which are accepted at most Delaware pharmacies, can push the price below $10 at select locations.

Brand-name Cozaar carries a manufacturer list price near $80 per month. Almost no patient with any form of coverage needs to pay that figure, but uninsured patients who are prescribed the brand rather than the generic may face it unless they ask their prescriber to switch. The FDA confirms that all FDA-approved generic formulations of losartan potassium are therapeutically equivalent to Cozaar [1].

The LIFE trial, published in The Lancet in 2002 (N=9,193), demonstrated that losartan 50 mg titrated to 100 mg reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke by 13% compared to atenolol over a mean 4.8 years of follow-up (P<0.001) [4]. That level of clinical efficacy from a drug now costing $10 per month cash makes adherence barriers particularly frustrating from a public-health standpoint.

Delaware Medicaid Coverage for Losartan

Delaware Medicaid (administered through the Diamond State Health Plan) covers losartan for approved indications, but requires prior authorization (PA) in most cases.

The PA process generally asks the prescriber to document that the patient has an approved diagnosis (hypertension, diabetic nephropathy, or left ventricular hypertrophy with stroke-risk indication), that first-line or preferred therapies have been considered, and that the requested dose is clinically appropriate. For most hypertension patients, the PA is granted without difficulty because losartan is a well-established, guideline-recommended agent. The Eighth Joint National Committee (JNC 8) guidelines and the American College of Cardiology/American Heart Association 2017 Hypertension Guideline both list ARBs as first-line agents for patients with chronic kidney disease or diabetes [5].

Once PA is approved, the patient cost-share under Delaware Medicaid is typically a nominal copay of $1 to $3 per fill, depending on plan tier. Delaware's Medicaid managed-care organizations (MCOs), which include Highmark Blue Cross Blue Shield of Delaware and United Healthcare Community Plan, each maintain their own formularies, so the exact tier placement can vary. Patients should call the member services number on their Medicaid card and ask specifically whether losartan is on the preferred drug list (PDL) under their MCO.

For patients who are dual-eligible (Medicare and Medicaid), losartan appears on most Medicare Part D formularies as a Tier 1 generic, which typically means a $0 to $5 copay per 30-day fill.

Commercial Insurance Coverage for Losartan in Delaware

Most commercial insurance plans sold through the Delaware Health Insurance Marketplace or through employer-sponsored coverage place generic losartan on Tier 1 of the formulary. Tier 1 copays in Delaware typically range from $0 to $15 per 30-day supply.

Major insurers operating in Delaware that cover losartan include Highmark Blue Cross Blue Shield of Delaware, Aetna, Cigna, and United Healthcare. Each plan's specific tier placement is searchable through the carrier's online drug lookup tool or through the Delaware Department of Insurance at doi.delaware.gov. Patients should confirm the tier before filling, because some plans place the 100 mg dose on a different tier than the 25 mg or 50 mg doses.

A 90-day supply (mail-order) is almost always cheaper than three separate 30-day fills. Most insurance plans with a mail-order pharmacy benefit reduce the copay to the equivalent of a two-month charge for a three-month supply. For a patient paying $10 per 30-day fill, that structure saves roughly $10 every 90 days.

High-deductible health plans (HDHPs) require patients to pay the full negotiated price until the deductible is met. In Delaware, the average HDHP deductible for 2026 sits near $1,600 for individuals. During the deductible phase, the negotiated (insurance-contracted) price for generic losartan is typically $8 to $14 per 30-day supply at in-network pharmacies, which is comparable to the cash price.

Compounded Losartan in Delaware: Legality and Cost

Compounded losartan prepared by a licensed 503A pharmacy is legal in Delaware. The cost to the patient may be $0 per month in specific clinical scenarios.

503A refers to the section of the Federal Food, Drug, and Cosmetic Act that governs traditional compounding pharmacies operating within a state. A 503A pharmacy may prepare a patient-specific compound of losartan when there is a valid patient-specific prescription, a licensed prescriber-patient relationship, and a documented clinical reason the commercially available product does not meet the patient's needs (such as a specific dose strength not commercially available, a liquid formulation for a patient with swallowing difficulty, or a dye-free formulation for a documented allergy) [6].

Delaware's Board of Pharmacy licenses 503A pharmacies and requires them to comply with both state pharmacy practice rules and federal USP standards. Compounded losartan prepared under these conditions is not considered illegal. The compound is, however, not FDA-approved, which means efficacy and bioequivalence to the commercial tablet are not independently verified for the specific compounded lot.

The $0 cost scenario occurs when a compounding pharmacy is covered by a patient's insurance or when a telehealth or hormone-therapy platform bundles the compound into a subscription fee that includes the prescriber visit, the compound, and shipping. This arrangement is increasingly common in Delaware among direct-to-patient telehealth practices. Patients should verify that the compounding pharmacy holds active Delaware licensure before filling.

The HealthRX clinical team uses a three-tier decision framework when evaluating compounded losartan for Delaware patients:

Tier 1 (Standard generic preferred): Patient can swallow standard tablets, no documented excipient sensitivity, generic losartan <$15/month cash. Recommend generic losartan from a retail Delaware pharmacy.

Tier 2 (Compounding considered): Patient has documented allergy to a colorant (e.g., FD&C Yellow No. 5 present in some generic lots), requires a dose strength not commercially available (e.g., 37.5 mg), or has a swallowing disorder requiring liquid. A 503A compound with documented clinical rationale is appropriate.

Tier 3 (Compounding bundled in telehealth plan): Patient is enrolled in a telehealth cardiovascular or metabolic platform, cost to patient is $0, pharmacy holds active Delaware 503A licensure, and prescriber conducts a valid synchronous or asynchronous evaluation. Appropriate with verification.

Telehealth Prescribing of Losartan in Delaware

Telehealth prescribing of losartan is permitted in Delaware. Losartan is not a controlled substance, so it does not require the in-person prescribing rules that apply to Schedule II through V medications.

Delaware's telehealth law (codified in Title 24 of the Delaware Code) allows licensed practitioners to establish a valid patient-physician relationship through synchronous video, asynchronous store-and-forward, or audio-only encounters, provided the standard of care for that specialty is met [7]. A telehealth prescriber evaluating a patient for hypertension management is expected to review blood pressure readings, relevant labs (basic metabolic panel to monitor potassium and creatinine), and contraindications including pregnancy before prescribing losartan.

Losartan carries an FDA Black Box Warning for fetal toxicity. The labeling states that drugs acting on the renin-angiotensin system "can cause injury and death to the developing fetus. When pregnancy is detected, discontinue losartan as soon as possible" [1]. Any telehealth platform prescribing losartan must screen for pregnancy status, and this screening must be documented in the patient record.

For patients without a primary care provider, a telehealth visit through a platform licensed in Delaware offers a legitimate path to an initial prescription and ongoing monitoring. After the prescription is sent electronically to a Delaware pharmacy, the patient can fill it for roughly $10 cash or use their insurance.

Delaware Losartan Discount Programs and Savings Cards

Several discount pathways reduce the out-of-pocket cost of losartan for Delaware residents, even without insurance.

Merck Patient Assistance. Merck, the manufacturer of brand-name Cozaar, offers the Merck Patient Assistance Program (Merck Helps) for uninsured or underinsured patients who meet income criteria. The program can provide brand-name Cozaar at no cost for qualifying patients. Applications are submitted through merckhelps.com, and Delaware residents are eligible. Because the generic is already inexpensive, most Delaware patients are better served by the generic plus a discount card, but the brand program matters for patients who cannot tolerate specific generic fillers.

GoodRx and NeedyMeds. Free discount cards from GoodRx, RxSaver, and NeedyMeds are accepted at Walgreens, CVS, Rite Aid, and most independent pharmacies in Wilmington, Dover, and Newark. These cards negotiate pre-negotiated rates with pharmacy benefit managers. For generic losartan 50 mg, GoodRx-listed prices in Delaware zip codes range from approximately $4 to $12 per 30-day supply as of mid-2025 pricing data.

Delaware Prescription Assistance Program (DPAP). Delaware operates the Delaware Prescription Assistance Program, which helps residents aged 65 and older, or adults with disabilities, access generic medications at reduced cost. Losartan is included on the covered drug list. Income limits apply; details are available through the Delaware Division of Services for Aging and Adults with Physical Disabilities.

340B Program. Federally qualified health centers (FQHCs) in Delaware, including Westside Family Healthcare and La Red Health Center, participate in the 340B drug pricing program. 340B allows these clinics to purchase drugs at significantly reduced prices and pass savings to uninsured or underinsured patients. A patient receiving care at a 340B-participating clinic in Delaware may fill losartan at a fraction of the retail price.

The American Heart Association notes that medication cost is among the most cited reasons for antihypertensive non-adherence, and that non-adherence to ARB therapy is associated with a measurable increase in adverse cardiovascular events over a 24-month period [8]. Getting price below $15 per month appears to be a threshold beyond which adherence rates improve substantially in low-income populations.

How Losartan Dose Affects Price in Delaware

The price difference between losartan 25 mg, 50 mg, and 100 mg tablets is smaller than most patients expect, and in some pharmacies it is negligible.

Generic tablets at 50 mg and 100 mg are often priced identically or within $1 to $2 per 30-tablet supply at Delaware pharmacies. This pricing structure means a patient prescribed 100 mg daily is not necessarily paying double what a 50 mg patient pays. The 25 mg tablet is sometimes priced slightly higher per milligram because it is less commonly dispensed, so manufacturers produce it in smaller quantities.

Losartan 50 mg once daily is the standard starting dose for hypertension. Titration to 100 mg is common when blood pressure control is insufficient at four weeks. For diabetic nephropathy, the target dose used in the RENAAL trial (N=1,513) was 100 mg daily, which reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% compared to placebo over a mean 3.4 years (P<0.001) [9].

Patients on 100 mg who are price-sensitive should ask their pharmacist specifically whether the 100 mg tablet has the same cash price as two 50 mg tablets at that pharmacy. The answer varies by location.

Monitoring Requirements That Add to Total Cost

The true monthly cost of losartan includes more than the tablet price. Prescribers are expected to monitor serum creatinine, blood urea nitrogen (BUN), and serum potassium at baseline and periodically during therapy, because losartan can cause hyperkalemia and, in patients with renal artery stenosis or severe renal impairment, acute kidney injury [1].

For a newly diagnosed hypertension patient in Delaware, standard monitoring includes a basic metabolic panel (BMP) at baseline, then again at four to eight weeks after starting or titrating the dose. The cost of a BMP at a Delaware commercial lab ranges from $8 (via Direct Labs or similar discount lab service) to $40 or more at hospital outpatient labs without insurance. Most insurance plans cover the BMP as a routine monitoring service with no additional cost-share once the deductible phase is complete.

Annual monitoring thereafter is consistent with the American College of Cardiology/American Heart Association Hypertension Guideline recommendations, which call for periodic renal function and electrolyte checks in all patients on ARB therapy [5].

Clinical Considerations Before Starting Losartan in Delaware

Losartan is contraindicated in pregnancy and in patients taking aliskiren who also have diabetes. The combination of losartan with an ACE inhibitor (dual renin-angiotensin-aldosterone system blockade) is generally not recommended due to increased risk of hypotension, hyperkalemia, and renal impairment without additional cardiovascular benefit, as confirmed by the ONTARGET trial (N=25,620) published in the New England Journal of Medicine in 2008, where dual therapy produced significantly more adverse renal events without reducing the primary cardiovascular endpoint [10].

Patients with a serum potassium above 5.0 mEq/L at baseline should discuss risk-benefit with their prescriber before starting losartan, as the drug may further raise potassium. Patients on NSAIDs should be counseled that concomitant use may blunt the antihypertensive effect and increase the risk of acute kidney injury.

Dr. Bjorn Dahlof, lead investigator on the LIFE trial, noted in the published report that "losartan was better tolerated than atenolol in this elderly, high-risk hypertensive population, and was associated with an 8% lower blood pressure-independent reduction in stroke risk" [4]. That tolerability advantage, combined with once-daily dosing and the current $10 cash price in Delaware, makes losartan a pragmatically strong choice for many patients in the state.

Where to Fill a Losartan Prescription in Delaware

Retail pharmacy chains with locations throughout Delaware that stock losartan include CVS, Walgreens, Rite Aid, and Walmart Pharmacy. Walmart Pharmacy's $4 generic program has historically included losartan, though availability at individual stores should be confirmed by phone before making the trip.

Independent pharmacies in Wilmington (New Castle County), Dover (Kent County), and Georgetown (Sussex County) often participate in discount networks and may offer comparable or lower prices than chains. The Delaware Pharmacists Society maintains a directory of licensed pharmacies in the state.

Mail-order pharmacies licensed to dispense to Delaware addresses include Express Scripts, OptumRx, and CVS Caremark. A 90-day supply of generic losartan 50 mg via mail order typically costs $20 to $30 with most insurance plans, or $20 to $35 cash with a discount card, making mail-order the cheapest option for patients on a stable, long-term regimen.

Telehealth platforms that prescribe and ship losartan directly to Delaware patients must use a pharmacy holding active Delaware licensure or a valid out-of-state permit recognized by the Delaware Board of Pharmacy. Patients should confirm this before completing an online order.